Bray George A
Pennington Biomedical Research Center of Louisiana State University, Baton Rouge, LA, USA.
Obesity (Silver Spring). 2008 Mar;16(3):509-14. doi: 10.1038/oby.2007.100. Epub 2008 Jan 31.
At any one time large numbers of people are attempting to control their weight. Women are the principal consumers of weight-control programs. Their options, outside the prescription drug market and surgical treatment, include diets and diet books, exercise alone or with supervision in exercise facilities, dietary supplements, group programs, doctors, dietitians, psychologists, and other health-care professionals. Non-prescription products available to help people control their weight cover a wide range, including herbal dietary supplements, diet drinks and portion-controlled foods, meal replacements, and low-carbohydrate diets and foods. The introduction of orlistat as an over-the-counter (OTC) product will provide the only Food and Drug Administration (FDA)-approved product for weight loss currently in that category since phenylpropanolamine (PPA) was withdrawn by the FDA. The FDA approval process is considerably more expensive than allowing untested herbal supplements to be marketed without testing, but the added safety evaluation by the FDA will reduce the risk of disastrous outcomes that have plagued many approaches to weight control. Support for a place for orlistat as an OTC product includes the inadequacy of current programs, empowerment of the public, lower cost, and bringing pharmacists into weight-control programs. The downside includes improper use of OTC orlistat that may not result in achieving individual expectations.
在任何时候，都有大量的人试图控制自己的体重。女性是体重控制项目的主要消费者。在处方药市场和手术治疗之外，她们的选择包括节食和减肥书籍、单独锻炼或在健身设施中接受监督的锻炼、膳食补充剂、团体项目、医生、营养师、心理学家以及其他医疗保健专业人员。可帮助人们控制体重的非处方产品种类繁多，包括草药膳食补充剂、减肥饮料和定量控制食品、代餐食品以及低碳水化合物饮食和食品。自从苯丙醇胺（PPA）被美国食品药品监督管理局（FDA）撤市以来，奥利司他作为一种非处方（OTC）产品的推出，将成为该类别中目前唯一获得FDA批准用于减肥的产品。FDA的审批过程比允许未经测试的草药补充剂在未经过测试的情况下上市要昂贵得多，但FDA增加的安全性评估将降低困扰许多体重控制方法的灾难性后果的风险。支持奥利司他作为OTC产品的理由包括当前项目的不足、赋予公众权力、降低成本以及让药剂师参与体重控制项目。不利之处包括OTC奥利司他的不当使用可能无法达到个人预期。
